15:00 , Mar 8, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of PD-L1, LGALS9 and XAGE-1b proteins could help predict survival in lung adenocarcinoma patients. In 120 patients, high tumor levels of PD-L1, low tumor levels of LGALS9 and low levels...
08:00 , Jan 29, 2015 |  BC Innovations  |  Strategy

PD-1 matchmaking

The rush to find combinations of PD-1 inhibitors and established cancer therapies marks the end of the beginning, rather than the beginning of the end, of the search for ways to extend use of checkpoint...
07:00 , Jul 31, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Asthma; multiple sclerosis (MS) Galectin-9 (LGALS9); tumor necrosis factor receptor superfamily member 9 (TNFRSF9; 4-1BB; CD137) Mouse...
08:00 , Nov 10, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Influenza virus Galectin-9 (LGALS9) Mouse studies suggest blocking LGALS9 signaling could improve immune responses to influenza...
08:00 , Jan 22, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer ...